LISATA THERAPEUTICS, INC. Annual Report Summary: A Look Back at 2025

Understanding a company's performance is crucial for any investor. This summary provides a clear, concise overview of LISATA THERAPEUTICS' (NASDAQ: LSTA) financial and operational highlights from its official Annual Report, or Form 10-K, for the fiscal year ended December 31, 2025. This comprehensive yearly filing with the SEC offers a detailed look at the company's progress and challenges.

LISATA THERAPEUTICS is a clinical-stage biotechnology company. It focuses on developing new treatments for challenging solid tumors using its proprietary CendR platform technology. The company's strategy involves moving its main drug candidates through clinical trials and seeking partnerships.

Company Status:

• Non-Accelerated Filer & Smaller Reporting Company: This classification means LISATA has slightly fewer reporting requirements than larger companies, but still provides essential operational and financial details.
• Not a "Shell Company": LISATA operates with real business activities and an active development pipeline, distinguishing it from a shell company.

Business Overview

LISATA THERAPEUTICS discovers and develops innovative treatments for difficult-to-treat solid tumors. Its core CendR platform technology aims to improve the delivery of anti-cancer agents to tumor cells. LISATA's main activities include preclinical research, managing clinical trials for its key drug candidates, and exploring collaborations to develop and commercialize its pipeline. The company seeks to meet significant unmet medical needs in oncology by enhancing the effectiveness and safety of cancer treatments.

Financial Performance Highlights for Fiscal Year 2025:

• Revenue: As a clinical-stage company, LISATA generated no significant product revenue in 2025, which aligns with its development stage. Any revenue typically stems from grants or collaboration agreements.
• Net Loss: The company reported a net loss of $45.2 million for 2025, an increase from $38.5 million in 2024. This wider loss primarily reflects greater investment in research and development as LISATA advances its clinical programs.
• Research & Development (R&D) Expenses: R&D spending increased to $35.8 million in 2025, up from $30.1 million in the prior year. This rise indicates active progression of its clinical programs and higher costs for ongoing trials.

Risk Factors

The report outlines several critical risks typical for a clinical-stage biotechnology company. These factors could significantly impact LISATA's business, financial health, and operating results. Investors should consider:

• Clinical Trial Uncertainty: Clinical trials face inherent uncertainty, with potential for setbacks, delays, or failures at any stage. Such outcomes could significantly affect the company's future and demand substantial additional investment.
• Funding Needs: LISATA requires significant additional funding to advance its drug candidates through later-stage trials, regulatory approval, and potential commercialization. The company may not secure this funding on favorable terms or at all.
• Regulatory Hurdles: The drug approval process, overseen by agencies like the FDA, is lengthy, unpredictable, and costly, posing significant regulatory challenges.
• Intense Competition: LISATA faces strong competition from larger pharmaceutical companies and other biotechnology firms. These competitors often have greater resources or more advanced products.
• Third-Party Reliance: The company depends on third parties for essential functions like manufacturing and clinical trials.
• Intellectual Property Protection: LISATA must effectively protect and enforce its intellectual property rights related to its CendR platform technology and drug candidates.

Management Discussion and Analysis (MD&A) Highlights

LISATA's operational and strategic developments in 2025 demonstrate its focus on advancing its clinical pipeline and strengthening its intellectual property.

• Clinical Pipeline Progress: LISATA successfully completed patient enrollment in its Phase 2 clinical trial for its lead drug candidate, which targets a specific cancer type. This marks a significant step toward potential market entry.
• New Trial Initiation: The company also initiated a new Phase 1b clinical trial for another drug candidate in combination with standard-of-care therapies for another cancer type. This expands its pipeline reach and explores new therapeutic avenues.
• Intellectual Property: LISATA continued to strengthen its intellectual property portfolio, securing three new patent issuances related to its CendR platform technology. These patents protect its core innovations and provide a competitive advantage.
• Research and Development Focus: The rise in R&D expenses highlights the company's commitment to its clinical programs and covers the costs of conducting multiple trials and preclinical studies.

Financial Health

LISATA's financial health, typical for a clinical-stage biotech, is mainly defined by its cash reserves and burn rate.

• Cash Position: As of December 31, 2025, LISATA reported $62.7 million in cash and cash equivalents. This marks a decrease from $105.3 million at the end of 2024, primarily due to higher R&D spending and general operating costs.
• Liquidity and Capital Resources: Based on its current operational spending rate, LISATA projects its cash will fund operations into mid-2027. However, the company will likely need additional capital to complete ongoing trials, start new ones, or pursue commercialization. LISATA expects to raise these funds through equity offerings, debt financing, or strategic partnerships.
• Debt: As a clinical-stage company focused on R&D, LISATA carries no significant long-term debt, typically funding its operations through equity.

Future Outlook

LISATA THERAPEUTICS remains focused on advancing its clinical development programs.

• Key Milestones: A critical anticipated milestone is the topline data from the Phase 2 clinical trial for its lead drug candidate, expected in Q3 2026. This data will be pivotal for the company's future direction and potential investor returns.
• Strategic Direction: The company plans to continue advancing its current pipeline, explore new indications or combination therapies, and evaluate potential strategic partnerships to maximize the value of its CendR platform technology.
• Capital Needs: LISATA acknowledges its need for substantial additional capital to fund operations beyond mid-2027 and to progress its drug candidates through later development stages and potential commercialization. Future financing activities will be crucial.

Competitive Position

The biotechnology industry, especially in oncology, is highly competitive, marked by rapid technological change and intense research and development. LISATA THERAPEUTICS competes with:

• Large Pharmaceutical Companies: These companies have significantly greater financial, technical, and human resources, often with established sales and marketing infrastructures.
• Other Biotechnology Companies: Many other clinical-stage and commercial-stage biotech firms are developing new solid tumor therapies. Some may be more advanced or use different mechanisms of action.
• Academic and Research Institutions: These entities also discover new therapies and may hold intellectual property that could affect LISATA's competitive landscape.

LISATA's competitive edge primarily stems from its proprietary CendR platform technology, which aims to improve drug delivery to tumors, offering a potentially differentiated approach. The company's intellectual property portfolio, including its recently secured patents, is vital for maintaining this edge. Its strategy involves demonstrating superior efficacy or safety profiles in clinical trials to differentiate its drug candidates in a crowded market.

Market Snapshot

• LISATA THERAPEUTICS trades on The Nasdaq Capital Market under the ticker symbol LSTA.
• As of June 30, 2025, the total value of its common stock held by public investors (public float) was approximately $23.6 million, based on a stock price of around $2.90 per share.
• As of March 12, 2026, 9,032,291 shares of its common stock were outstanding.

Conclusion

LISATA THERAPEUTICS actively advanced its clinical pipeline with significant R&D investment in 2025. While the company navigates the typical financial demands and clinical development risks of an early-stage biotech, the upcoming year features crucial data readouts that will be pivotal for its future trajectory and potential investor returns.